Introduction {#s1}
============

Prevalence of central nervous system (CNS) diseases increases with age, either directly, by a time-dependent accumulation and aggregation of abnormal proteins, e.g., in Alzheimer's, Parkinson's, and Huntington's disease, or indirectly, due to the increase in age-related changes that foster the onset and/or progression of brain diseases. For example, stroke is associated with a high risk of seizures and epilepsy, while type 2 diabetes and atherosclerosis are a risk factor for Alzheimer's and cerebrovascular disease (Lénárt et al., [@B28]; Beghi and Giussani, [@B4]; Hou et al., [@B22]).

On the other hand, inflammation is a well-recognized pathogenic factor in age-associated disorders, neurological disorders included. A role for chronic, low level, systemic inflammation is hypothesized in psychiatric conditions, epilepsy, cerebrovascular diseases, dementia and neurodegeneration (Vezzani et al., [@B54]; Najjar et al., [@B33]; Lénárt et al., [@B28]; Guzman-Martinez et al., [@B20]; Ignácio et al., [@B24]).

The P2X7 receptor (P2X7R) is an ATP-gated cation-selective channel involved in inflammation and host defense. P2X7R activation promotes the release of several pro-inflammatory factors, both in the CNS and in peripheral tissues, and is understood to participate in the pathogenesis of several neurodegenerative diseases such as multiple sclerosis, Alzheimer's, Parkinson's, and Huntington's disease (Savio et al., [@B41]; Kanellopoulos and Delarasse, [@B25]). The P2X7R is also involved in the pathogenesis of age-related pathologies such as cancer, osteoporosis, diabetes and arthritis (Tao et al., [@B50]; Kvist et al., [@B26]; Sperlágh and Illes, [@B49]; Novak and Solini, [@B34]; Adinolfi et al., [@B1]). The strong pro-inflammatory activity of the P2X7R depends on the ability of this receptor to trigger the generation of reactive oxygen species and release of cytokines and metalloproteases. Some of these responses are mediated through the stimulation of the NLRP3 inflammasome and of caspase-1. P2X7R activation may have opposite effects on cell growth; low level, tonic stimulation promotes cell proliferation, while sustained stimulation triggers cell death by necrosis or apoptosis (Di Virgilio, [@B11]). P2X7R-dependent cytotoxicity can be exploited for intracellular pathogen killing (Adinolfi et al., [@B2]).

*P2RX7* is a highly polymorphic gene located on chromosome 12q24.31. The most studied *P2RX7* single nucleotide polymorphism (SNP) is the 1513A\>C. Homozygous subjects carrying the 1513CC genotype show a non-functional P2X7R pore and a reduced ability to activate inflammation compared to wild-type subjects bearing the AA genotype (Wesselius et al., [@B55]). The possible association of the 1513CC *P2RX7* genotype with different inflammatory conditions is attracting increasing interest (Di Virgilio et al., [@B12]). Other important *P2RX7* SNPs are the loss-of-function 1405A\>G, and the gain-of-function 489C\>T and 1068G\>A (Sluyter and Stokes, [@B46]; Caseley et al., [@B8]).

In the present study, we tested the hypothesis of an association between age and frequency among polymorphic P2X7 receptor genotypes. To this aim, we carried out a revision of the relevant literature and the analysis of two dbGaP (database Genotype and Phenotype) datasets.

Materials and Methods {#s2}
=====================

Publication Search Strategy {#s2-1}
---------------------------

A Medline literature search using the keywords rs3751143, 1513A\>C, or E496A, which identify the *P2RX7* SNP of interest, allowed a partial retrieval of all pertinent studies. Therefore, the search was extended to the keyword mesh "(P2X7 or P2X7R or P2RX7) and (polymorphism or polymorphisms)." In July 2016, this search produced 178 hits, from which 79 articles analyzing the frequency of 1513A\>C *P2RX7* SNP were selected. Forty seven studies were excluded because: (a) two were based on small cohorts (16 and 46, respectively); (b) seven analyzed only diseased subjects, with no cohorts comprising healthy controls; (c) four reported data from already published control cohorts; (d) one article was not found; and (e) the remaining 33 studies did not specify the mean or median age and/or CC frequency of the control cohorts. Thirty-two studies involving a total 34 cohorts (Zhang et al., [@B59]; Fernando et al., [@B14] articles describe two different control cohorts) with 11,858 subjects, were thus identified. With the exception of the study by Sambasivan (Sambasivan et al., [@B39]), genotype distribution in all control cohorts was in Hardy--Weinberg equilibrium (HWE).

dbGaP Analysis {#s2-2}
--------------

We received NIH approval to analyze two datasets comprising *P2RX7* SNPs in Caucasian control cohorts which report the age of enrolled subjects:

1.  HGVST1 (Human Genoma Variation ST1); Study of prostate cancer; dbGaP Study Accession, phs000207.v1.p1. Dataset Name: CGEMS (The Cancer Genetic Markers of Susceptibility) Prostate_Data; Dataset Accession, pht001105.v1.p1); NIH approval, \[\#47650-2\] \[\#47650-4\]. It is a nested case-control study to identify SNP associated to augmented prostate cancer susceptibility. Control cohort include 1,101 men with European ancestry selected from The Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial from USA (Yeager et al., [@B58]).

2.  HGVST6; Study of Parkinson's Disease; dbGaP Study Accession, phs000089.v3.p2; Dataset Name cde_ctl. Dataset Accession, pht000177.v3.p2; NIH approval accession: \[\#47649-3\]. This case-control study analyzed genetic variants that may increase risk of Parkinson's disease in the collection of North American Caucasians with Parkinson's disease, as well as neurologically normal controls from the sample population which are banked in the National Institute of Neurological Disorders and Stroke (NINDS Repository) collection (Fung et al., [@B16]). The control cohort is composed of 802 Caucasian subjects, about 60% are women, and more than 95% of the subjects originate from the USA. Each participant underwent a detailed medical history interview and had no family history of Alzheimer's disease, amyotrophic lateral sclerosis, ataxia, autism, bipolar disorder, brain aneurysm, dementia, dystonia, or Parkinson's disease.

In these control cohorts, we have searched 16 characterized *P2RX7* SNPs (Sluyter and Stokes, [@B46]) out of more than 300,000 SNPs reported in the databases, but only four polymorphisms were identified. The main published features of these *P2RX7* SNP polymorphisms are shown in [Table 1](#T1){ref-type="table"}.

###### 

Principal published characteristics of *P2RX7* SNP polymorphisms.

              Base change   Amino acid change   Effect on function   Minor allele frequency
  ----------- ------------- ------------------- -------------------- ------------------------
  rs2230912   1405A \> G    Gln460Arg           Partial loss         0.17
  rs3751143   1513A \> C    Glu496Ala           Loss                 0.175
  rs1718119   1068G \> A    Ala348Thr           Gain                 0.400
  rs208294    489C \> T     His155Tyr           Gain                 0.439

In the HGVST6 dataset, individual subject age was specified, while in the HGVST1 dataset only decade age was reported, therefore to make data from both datasets homogenous, subjects from the HGVST6 study were re-comprised in the same age decade sub-cohorts as the HGVST1 study, as follows: decade \# 3, age range 15--29 (number of subjects, 51); decade \# 4, age range 30--39 (number of subjects, 77); decade \# 5, age range 40--49 (number of subjects, 99); decade \# 6, age range 50--59 (number of subjects, 280); decade \# 7, age range 60--69 (number of subjects, 821); decade \# 8, age range 70--79 (number of subjects, 507); decade \# 9, age range 80--94 (number of subjects, 68). Age decade \# 3 was not included in the analysis due to its small number of subjects and because, according to the USA Center for Diseases Control and Prevention (CDC) and the Word Health Association (WHO), the three main causes of death between 15 and 30 years are unintentional injury, suicide and homicide (more than 70% of total deaths), none of which are associated with inflammation[^1^](#fn0001){ref-type="fn"},[^2^](#fn0002){ref-type="fn"}. All four *P2RX7* SNPs analyzed were in the HWE across all age decades, with the exception of the gain-of-function rs208294 SNP in age decade \# 5 (*p* = 0.037).

Statistical Analysis {#s2-3}
--------------------

Data on the rs2230912, rs3751143, rs1718119, rs208294 genotypes, and the age of the subjects enrolled in the two dbGaP datasets, were extracted using SAS 9.4 (SAS Institute, Cary, NC, USA), and analyzed by correlation analysis using the GraphPad InStat 3 software (Graphpad Software, San Diego, CA, USA). The KS normality test (Kolmogorov--Smirnov tests with Dallal--Wilkinson--Liliefor *P*-value) was applied, and the Pearson correlation coefficient was calculated. Statistical significance was assumed as *p* \< 0.05 for the initial rs375114 studies. When we subsequently analyzed data from the dbGaP and tested three other P2X7 SNPs as a secondary objective (considering eight test hypotheses and according with the Bonferroni correction), statistical significance was reduced to *p* \< 0.00625.

Results and Discussion {#s3}
======================

The 1513A\>C *P2RX7* SNP was initially identified in monocytes from a healthy subject with a nonfunctional P2X7 (Gu et al., [@B19]). Later it was associated with many different diseases, including tuberculosis, Crohn's disease, rheumatoid arthritis, and psychiatric disorders (Sluyter and Stokes, [@B46]). Our previous studies showed a higher frequency of the 1513CC *P2RX7* genotype in aged compared with young cohorts, but the sample size was rather small (Cabrini et al., [@B6]; Dardano et al., [@B10]; Sanz et al., [@B40]). Thus, we decided to perform a wide range literature search in PubMed, using the queries "(P2X7 or P2X7R or P2RX7) and (polymorphisms or polymorphism)." Source and data extracted from 34 healthy cohorts specifying mean or median age (29 and 5 cohorts, respectively) and CC % frequency, analyzed across 32 articles, are shown in [Table 2](#T2){ref-type="table"}.

###### 

Age and 1513CC *P2RX7* genotype frequency in different population cohorts.

  Cohort origin    Mean/Median age (years) ± SD (age range)   Genotype 1513CC Freq. (%)   Subjects number   References
  ---------------- ------------------------------------------ --------------------------- ----------------- -------------------------------
  China            5.9 ± 4.0 (0.25--16)                       11.5                        384               Xiao et al. ([@B57])
  Turkey           7.8 ± 4.9                                  2.6                         192               Tekin et al. ([@B52])
  United Kingdom   [29]{.ul} (10--49)                         3.0                         235               Zhang et al. ([@B59])
  Gambia           30.3 ± 7.5                                 1.3                         297               Li et al. ([@B29])
  Russia           32.2 ± 12.0 (21--71)                       2.4                         126               Mokrousov et al. ([@B32])
  Peru             32.6 ± 9.4                                 3.3                         513               Taype et al. ([@B51])
  Brazil           32.8 ± 16.5                                3.0                         263               de Salles et al. ([@B38])
  Oman             35 ± 7                                     8.2                         158               Al-Shukaili et al. ([@B3])
  Tunisia          35 (24--55)                                4.0                         150               Ben-Selma et al. ([@B5])
  India            35.6 ± 13.3                                8.0                         100               Sambasivan et al. ([@B39])
  Brazil           35.8 ± 12.0                                5                           288               Souza de Lima et al. ([@B48])
  Turkey           36.3 ± 19.7 (2--86)                        3                           120               Somuk et al. ([@B47])
  India            36.4 ± 14.9                                2.8                         392               Singla et al. ([@B45])
  China            37.2 ± 16.6 (9--80)                        6.2                         532               Chen et al. ([@B9])
  Australia        37.8 ± 13.0                                3.9                         102               Fernando et al. ([@B14])
  Turkey           39.3 ± 13.8                                13.1                        160               Özdemir et al. ([@B37])
  Germany          39.8 ± 11.4                                4.6                         461               Erhardt et al. ([@B13])
  Korea            [40.7]{.ul}                                4.0                         150               Lee et al. ([@B27])
  Iran             43                                         1.0                         100               Shamsi et al. ([@B43])
  Italy            44.1 ± 12.8                                2.0                         100               Dardano et al. ([@B10])
  Denmark          44.6 ± 12.2 (21--88)                       2.1                         808               Hansen et al. ([@B21])
  Australia        46.1 ± 8.9                                 4.2                         167               Fernando et al. ([@B14])
  Italy            46.7 ± 11.1                                3.8                         131               Ghiadoni et al. ([@B17])
  China            47.0 ± 14.5                                10.4                        87                Wu et al. ([@B56])
  Denmark          50.7 (45--58)                              2.7                         1,764             Ohlendorff et al. ([@B36])
  India            55.2 (40--80)                              1.7                         177               Sharma et al. ([@B44])
  United Kingdom   [58]{.ul} ± 12                             4.0                         428               Sellick et al. ([@B42])
  United Kingdom   [*58*]{.ul} (50--90)                       3.5                         113               Zhang et al. ([@B59])
  Sweden           [61]{.ul} (49--75)                         5.0                         200               Thunberg et al. ([@B53])
  Germany          62                                         5.2                         97                Nückel et al. ([@B35])
  Sweden           63 ± 6.5                                   3.2                         2,404             Gidlöf et al. ([@B18])
  Denmark          65.3 ± 8.2                                 3.5                         226               Husted et al. ([@B23])
  China            71.8 ± 6.1                                 2.8                         285               Liu et al. ([@B31])
  Italy            73 ± 5.6 (65--93)                          7.4                         148               Sanz et al. ([@B40])

*Age is specified as found in the original reference: Mean ± SD or [Median]{.ul} (age range)*.

Cohorts were further subdivided into two groups, European (13 articles comprising 14 cohorts) and non-European (19 articles comprising 20 cohorts). Ethnic origin of the cohorts was specified in five European studies (Caucasian origin) and in six non-European studies (non-Caucasian origin). In the remaining cohorts, ethnic origin was not specified, and healthy control subjects were local volunteers. Thus, it was assumed that the majority of the participants belonged to the prevalent ethnicity in the given country.

Linear regression analysis of the association between 1513CC *P2RX7* frequency and age from all cohorts, both European and non-European, is shown in [Figure 1](#F1){ref-type="fig"}. Analysis of pooled data from all cohorts showed no correlation between 1513CC *P2RX7* frequency and age. Likewise, no correlation between 1513CC *P2RX7* frequency and age was observed in non-European cohorts. On the contrary, subgroup analysis of European cohorts showed a significant correlation of 1513CC *P2RX7* frequency with age (*p* = 0.027). Separate analysis of European countries with three or more cohorts: Italy (Dardano et al., [@B10]; Ghiadoni et al., [@B17]; Sanz et al., [@B40]), Denmark (Ohlendorff et al., [@B36]; Hansen et al., [@B21]; Husted et al., [@B23]), and the United Kingdom (Starczynski et al., [@B100]; Zhang et al., [@B59]; Sellick et al., [@B42]), numbering three, three, and four cohorts respectively, showed a trend of increase in 1513CC *P2RX7* frequency with age.

![Association of 1513CC P2X7 genotype frequency with the age in All, European and Non-European cohorts. Legend. Corr. Coef., Pearson correlation coefficient. N: cohort number (total number of subjects).](fnmol-13-00008-g0001){#F1}

To further validate data derived from the literature, we analyzed 1513CC frequency in 1903 Caucasian control subjects included in the HGVST1 and HGVST6 studies. As a secondary objective, three other *P2RX7* SNPs (namely, the 489C\>T loss-of-function, the 1068G\>A and 1405A\>G gain-of-function SNPs) were also included in this analysis ([Table 3](#T3){ref-type="table"}).

###### 

*P2XR7* genotype frequency in HGVST1 and HGVST6 dataset.

               Hypomorphic P2X7R    Intermediate P2X7R   Hypermorphic P2X7R     Minor allele frequency   Number of subjects\*
  ------------ -------------------- -------------------- ---------------------- ------------------------ ----------------------
  1405A \> G   GG (%) 44 (2.3%)     AG (%) 540 (28.4%)   AA (%) 1,318 (69.3%)   0.165                    1,902
  1513A \> C   CC (%) 61 (3.3%)     AC (%) 602 (32.5%)   AA (%) 1,192 (64.3%)   0.195                    1,855
  1068G \> A   GG (%) 701 (37%)     AG (%) 932 (49.2%)   AA (%) 263 (13.9%)     0.384                    1,896
  489C \> T    CC (%) 543 (28.5%)   CT (%) 993 (52.2%)   TT (%) 367 (19.3%)     0.454                    1,903

*\* Number subject varies because for some individuals some genotypes are non-specified in the datasets*.

Hypomorphic and hypermorphic P2X7R genotype frequency of all SNPs at different age decades was analyzed to verify either a frequency increase in hypomorphic receptor or a frequency decrease of hypermorphic receptor with age ([Table 4](#T4){ref-type="table"}). A statistically-significant association between the increase in hypomorphic 1513CC and 489CC genotype frequency with age was found, and a reduction in the hypermorphic 1068AA genotype frequency with age was observed, but statistical significance was not reached. Instead, 1405A\>G SNP frequency was independent of age ([Figure 2](#F2){ref-type="fig"}). It is worth mentioning that a decreased frequency of a gain-of-function SNP (308GG) with age has also been reported for the potent pro-inflammatory cytokine TNFα (Cardelli et al., [@B7]).

###### 

Correlation analysis of *P2XR7* genotype frequency with age decade.

  SNP          Hypomorphic P2X7R   Hypermorphic P2X7R                                    
  ------------ ------------------- -------------------- ------------ -------- ---------- --------
  1405A \> G   1405GG              −0.4826              0.3323       1405AA   −0.00817   0.9877
  1513A \> C   1513CC              0.9390               0.0055^\#^   1513AA   −0.4904    0.3234
  1068G \> A   1068GG              0.3983               0.4342       1068AA   −0.8184    0.0465
  489C \> T    489CC               0.9359               0.0019^\#^   489TT    −0.08178   0.8616

*^\#^*p* \< 0.00625*.

![Association of P2X7 genotypes frequency with age decade in Caucasian control cohort.](fnmol-13-00008-g0002){#F2}

Differences in 1513CC frequency between European/USA and non-European/non-USA cohorts may be due to ethnic background, as previously reported for immune system-related genes, *P2RX7* included (Lindenau et al., [@B30]). Also, as suggested by Fuller et al. ([@B15]), environmental factors and prevalent diseases might also cause an allelic selection of *P2RX7* SNPs. Environmental factors, such as hygienic conditions, climate, and food availability, which are extremely variable in different areas of world, have a strong influence on disease prevalence and life expectancy. In low-income countries, nearly 40% of deaths occur in childhood (0 to 15-years age range), while only 20% occur among aged people (70 years and older). In these countries, morbidity and mortality are mainly due to infectious diseases (e.g., lower respiratory tract infections, HIV/AIDS, diarrheal diseases, malaria, and tuberculosis) that collectively account for almost one third of all deaths (World Health Organization data). The P2X7R has been reported to have a protective action against some common infective pathogens, such as Plasmodium, Mycobacterium, and Chlamydia. In high-income countries, however, 70% of deaths occur among people aged 70 years and older, the main causes being chronic diseases where inflammation plays an important and detrimental role, including cardiovascular disease, cancer, dementia, chronic obstructive pulmonary disease, and diabetes (World Health Organization data). Under these conditions, reduced activity of a potent pro-inflammatory receptor such as the P2X7R may turn out to be beneficial. Finally, a limitation of our study is the reduced sample size. Further replication studies are needed to test our hypothesis.

Conclusion {#s4}
==========

Based on these results, we hypothesize that in Caucasian elderly populations from high-income countries, where a hypofunctional P2X7R might afford protection against prevalent chronic inflammatory diseases, hypomorphic *P2RX7* alleles may be positively selected with age. This hypothesis suggests that the P2X7R might be a therapeutic target to alleviate inflammatory brain disorders and others age-related diseases.
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